Equities research analysts expect Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to report $68.38 million in sales for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Enanta Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $67.00 million and the highest estimate coming in at $70.80 million. Enanta Pharmaceuticals posted sales of $75.93 million during the same quarter last year, which suggests a negative year over year growth rate of 9.9%. The business is expected to report its next earnings report on Monday, November 19th.
On average, analysts expect that Enanta Pharmaceuticals will report full-year sales of $207.80 million for the current fiscal year, with estimates ranging from $206.42 million to $210.22 million. For the next year, analysts forecast that the firm will report sales of $222.42 million, with estimates ranging from $182.86 million to $259.85 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Enanta Pharmaceuticals.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported $0.97 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.98 by ($0.01). Enanta Pharmaceuticals had a return on equity of 25.84% and a net margin of 37.63%. The company had revenue of $57.26 million during the quarter, compared to the consensus estimate of $56.59 million.
A number of equities analysts recently issued reports on the stock. BidaskClub raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 22nd. Oppenheimer set a $100.00 price target on shares of Enanta Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, August 14th. Zacks Investment Research downgraded shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 10th. UBS Group downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 8th. Finally, JMP Securities restated a “buy” rating and issued a $120.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, July 31st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $107.60.
In other Enanta Pharmaceuticals news, VP Nathalie Adda sold 4,155 shares of the company’s stock in a transaction dated Monday, August 20th. The shares were sold at an average price of $92.32, for a total value of $383,589.60. Following the sale, the vice president now owns 4,465 shares in the company, valued at $412,208.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Tim Ocain sold 25,000 shares of the company’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $83.64, for a total transaction of $2,091,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,355 shares of company stock worth $3,500,462. Corporate insiders own 10.56% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new stake in shares of Enanta Pharmaceuticals during the first quarter valued at approximately $112,000. Zeke Capital Advisors LLC purchased a new stake in shares of Enanta Pharmaceuticals during the second quarter valued at approximately $216,000. Sei Investments Co. grew its holdings in shares of Enanta Pharmaceuticals by 63,966.7% during the first quarter. Sei Investments Co. now owns 1,922 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 1,919 shares during the last quarter. Meeder Asset Management Inc. grew its holdings in shares of Enanta Pharmaceuticals by 123.4% during the second quarter. Meeder Asset Management Inc. now owns 2,317 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 1,280 shares during the last quarter. Finally, Xact Kapitalforvaltning AB purchased a new stake in shares of Enanta Pharmaceuticals during the second quarter valued at approximately $290,000. Institutional investors and hedge funds own 77.62% of the company’s stock.
ENTA stock traded down $0.84 during trading on Wednesday, reaching $77.40. The company had a trading volume of 248,800 shares, compared to its average volume of 241,067. Enanta Pharmaceuticals has a 52 week low of $44.52 and a 52 week high of $127.77. The company has a market cap of $1.66 billion, a P/E ratio of 83.69 and a beta of 0.80.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Featured Article: S&P 500 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.